Lemstra Afina W, Eikelenboom Piet, van Gool Willem A
Department of Neurology, Academic Medical Center, Amsterdam, The Netherlands.
Gerontology. 2003 Jan-Feb;49(1):55-60. doi: 10.1159/000066508.
Cholinesterase inhibitors are licensed for treatment of dementia in Alzheimer's disease. However, the effects of these drugs on the cognitive symptoms of dementia are very small. We suggest that symptoms like impairment of attention and concentration, anxiety, restlessness and hallucinations, delineate a specific central cholinergic deficiency syndrome (CDS), that may be a much better target for such treatment. Changes in the quantitative electroencephalogram, muscarinic subtype radioimaging and serum anticholinergic activity may potentially help to diagnose the CDS. CDS is suggested to occur in various neurodegenerative diseases like Alzheimer's disease, Lewy body dementia and Parkinson's disease and to respond well to cholinesterase inhibitor therapy.
胆碱酯酶抑制剂被批准用于治疗阿尔茨海默病性痴呆。然而，这些药物对痴呆认知症状的影响非常小。我们认为，注意力和专注力受损、焦虑、烦躁不安和幻觉等症状描绘了一种特定的中枢胆碱能缺乏综合征（CDS），这可能是此类治疗更好的靶点。定量脑电图、毒蕈碱亚型放射性成像和血清抗胆碱能活性的变化可能有助于诊断CDS。CDS被认为发生在各种神经退行性疾病中，如阿尔茨海默病、路易体痴呆和帕金森病，并且对胆碱酯酶抑制剂治疗反应良好。
